Tianshui Zhongxing Bio-Technology Co. Ltd. Class A

As of June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A carries a market capitalization of 4.26B, placing it among publicly traded companies globally. Its enterprise value stands at 5.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A has 374.74M shares outstanding.

As of June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 12.44. The price-to-sales ratio is 1.99, and the price-to-book ratio stands at 1.20.

As of June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A trades at an EV/EBITDA multiple of 16.85 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.85 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 5.81B versus a market cap of 4.26B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A maintains a current ratio of 2.24, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 100.05, indicating elevated leverage, while an interest coverage ratio of 5.34 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A posted a return on equity (ROE) of 9.91, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.29 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.85, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.25, useful for judging operating efficiency across full business cycles. The company generates approximately 256,082.80 in revenue per employee across its workforce of 8,370.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.02 indicates how many times Tianshui Zhongxing Bio-Technology Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A's stock has declined approximately 12.82% over the past 52 weeks. The 50-day moving average sits at 10.85, while the 200-day moving average is 13.98.

Over the twelve months ended June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A generated 2.14B in revenue and converted that into 342.28M in net income, yielding earnings per share of 0.90. EBITDA reached 344.74M, while operating income came in at 369.72M.

As of June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A holds 2.01B in cash and equivalents against 3.57B in total debt, resulting in a net debt position of 763.99M. Total book value stands at 3.56B, with working capital of 2.11B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A posted a gross margin of 29.42, reflecting its pricing power and cost economics. The operating margin of 17.25 and net profit margin of 15.97 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A paid dividends of 0.96 per share. The dividend payout ratio of 104.97 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -14.76, meaning Tianshui Zhongxing Bio-Technology Co. Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Tianshui Zhongxing Bio-Technology Co. Ltd. Class A's most recent stock split took place on April 15, 2016 with a 39:80 split ratio.

As of June 30, 2026, Tianshui Zhongxing Bio-Technology Co. Ltd. Class A has an Altman Z-Score of 1.63, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.